Efficacy of combination tablet of angiotensin receptor blocker and high dose calcium channel blocker in essential hypertensio
Not Applicable
- Conditions
- patients with essential hypertension
- Registration Number
- JPRN-UMIN000016704
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
pregnant women or women who are possibly pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood pressure reduction
- Secondary Outcome Measures
Name Time Method Changes in - endothelial function(FMD), atherosclerosis (CAVI) - urinary protein and albumin and eGFR - uric acid - plasma renin activity, aldosterone, prorenin, and soluble (pro)renin receptor
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ARB-CCB synergy in blood pressure regulation for essential hypertension?
How does ARB-CCB combination compare to standard dual therapy in hypertension management?
Which biomarkers predict response to ARB-CCB combination in resistant hypertension subtypes?
What are the safety profiles of high-dose CCB-ARB combinations versus monotherapies?
What alternative antihypertensive regimens target renin-angiotensin-calcium pathways synergistically?